Glargine, Diabetic Ketoacidosis (DKA) and Cats
We are all familiar with the benefits of using glargine for the long-term management of our feline diabetic patients however, a new study evaluates its use in the setting of diabetic ketoacidosis (DKA). When administered intravenously or intramuscularly (IM) in humans, glargine has a similar onset and duration of action as regular insulin. In the study 15 cats with DKA were were given 1-2 U/cat of glargine IM at intervals of 2 or more hours. In 12/15 cats, 1-3 U/cat of subcutaneous glargine was also administered every 2 hours. All cats survived to discharge with a median hospital stay of 4 days.